UNSPSC 51363104: Ectylurea

This classification denotes a sedative and hypnotic with the molecular formula C7H12N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1U73ZZU4JK, chemically known as 2-butenamide, n- (aminocarbonyl)-2-ethyl-, (z)- but generally known as ectylurea, which bears US NIH Compound Identifier 7214. European Medicines Agency schedules Ectylurea in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06452MIG.

UNSPSC 51363104 Ectylurea is a Commodity code under which state and local governments procure pharmaceutical products, naloxone, drug deactivation systems, and over-the-counter medicines for public health, community health, and employee benefit programs. The recent solicitations show actual procurement spanning naloxone and drug deactivation systems for emergency response and community health use, generic multi-source pharmaceuticals and OTC products for distribution through state purchasing cooperatives, and direct-to-manufacturer prescription fulfillment programs to optimize pharmacy benefit costs. Issuing bodies include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances serving state agencies and local government facilities. The code attracts both product manufacturers and authorized pharmaceutical wholesalers as bidders, with vendors required to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act requirements, and specific insurance and E-Verify standards.

Recent activity spans multiple regions and procurement instruments. Seminole County, Florida released IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Minnesota Department of Administration issued an RFP through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) in January 2026 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, requiring vendors to maintain relationships with three authorized wholesalers and meet specific pricing, cGMP, and EDI capability standards. The Texas Health and Human Services Commission posted Request for Information HHS0017013 in April 2026 to explore direct-to-manufacturer prescription programs for self-insured health plans and state agencies. The code shows activity across Florida, Minnesota (serving participating states including Oregon), and Texas, with procurement spanning county health departments, state pharmacy benefit programs, and cooperative purchasing vehicles that serve multiple jurisdictions.